Posted on Authorea 18 Dec 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160827342.27683628/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. u-eia udwr nrae,Fgr ,adh tre opnc ohn a hne nhslf style life his in changed was Nothing panic! the to and leakage started opin- The medical he second again. and for ordered 2, sought were Figure sug- He Unfortunately tests ASAP. was increased, affected. same before approach was were the as job watch and fluid same his and ophthalmologist; Sub-retinal the and well-known wait be progressed another and to symptoms self-limiting from eye started is his ion his also weeks was needed but 3 Eplerenone common he almost only electrophysiologist topical after yet. not an 2% is unknown was but as disease negative However, He is this were CSC. gested. etiology that all of which reassured definite was favor usage; the steroid He in of and ago. both history months 1. were also 2 and angiography Figure therapy since history and Minoxidil after, appropriate medical OCT day the past PDT. his decide the ordered about therapy to he (OCT) asked angiography photodynamic examination tomography Fluorescein eye of coherence performed dilated plausibility optical ophthalmologist After and underwent his ophthalmologist. Bozorgi OCT domi- his with scotoma by Dr. central Along examined and was imaging. metamorphopsia He probable retinal with eye. its presented for right Bozorgi) and the (A. CSC in cardiologist healthy nantly about old views years our 39 of A share one to to decided happened was we Presentation which Bozorgi), Case report Ali case have this (Dr. hyperpermeability In article pathophysiology cause. choroidal entity[5]. this preventable its multifocal this of of and of aware authors pathophysiology compromise be take the the vascular to to for us Choroidal physicians suggested mandate urge However; recurrence factors. been which unnecessary. of risk symptoms be rates related may visual high and treatment addition, bothering and In and present- self-limiting frequent limitation measures[4]. main often a treatment the occupational is also are and CSC causes scotoma pre- disease Acute CSC central retinal sleep which CSC. and chronic common acute Metamorphopsia obstructive eye most in or impairment[3]. fourth the symptoms visual usage the of ing moderate is steroid to segment this hypertension, mild reports, posterior of personality, latest cause A of the to type disease According with common apnea[2]. men[1] a young is affects (CSC) dominantly chorioretinopathy specifically serous history Central drug full taking worth Introduction it CSC with words: patient Minoxidil’s Key of a column face reaction you adverse Minoxidil. whenever into and way steroid Hence, its finds leaflet. probably drug (CSC) chorioretinopathy serous was Central alopecia androgenic the message be for may clinical Minoxidil Minoxidil Key topical diagnosed. of was CSC applying work-up, months medical two full of After CSC. history scotoma. for central culprit with and cardiologist metamorphopsia healthy with presented old years 39 A Abstract 2020 18, December fate? 1 it is or bozorgi coincidence ali a just (eye), I and Minoxidil ffiito o available not Affiliation 1 lrz Khodabande Alireza , ioii,Cnrlsru chorioretinopathy serous Central Minoxidil, 1 n ae hosseini kaveh and , 1 1 Posted on Authorea 18 Dec 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160827342.27683628/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. BadK:Gtee l lnclmtrasadiae.AH eie h aucit BadKH: and AB al., manuscript. baldness. et the F., revised Scarinci, 1. AKH: manuscript. images. of version and initial References materials the drafted clinical and all literature the Gathered Reviewed KH: and AB CONTRIBUTION AUTHOR IR-TUMS.VCR.REC.1399.456 Code: Approval Ethical INTEREST: OF CONFLICT Minoxidil. you and whenever consent steroid is: specifically Informed staffs history and drug researchers full medical taking the worth Funding: to it article CSC first this with the of patient is message a Minoxidil important face of an discontinuation be and Eplerenon. may treatment by Finally, improve CSC report, not in their did 41 placebo to CSC a than Compared and in more shorter situation. was CSC no option[8]. this usage and is in Minoxidil usage Eplerenon therapy of Minoxidil think effective duration We term the an long presentation as case between suggested our relation was column in the Eplerenon reaction postulated adverse man. also into old has way years report its case finds article a CSC this Recently Rastmanesh, on based Dr. leaflet. future, and gain, the drug Sancrini weight into Minoxidil’s unusual Possibly, Dr. of pain, mentioned[1], by chest also studies fainting, were previous is dizziness, vision pathophysiology. and presentation blurred hair, CSC and in facial/body case Conjunctivitis unwanted Minoxidil this three are between of etc. in Minoxidil of role coincidence symptoms of causal a feature patients effects the just and unique Side of is edema favor the retinal this in of However, be deterioration is May confirmative and This Minoxidil population. a note. weeks. of not of male dosage is is young in usage there increase in cell unwanted Minoxidil date, involved. things also glial To are and common mechanisms causes CSC [7]. two on one which of CSC than Minoxidil prevalence receptor in more high of involved be 4 The effect may be Aquaporin mechanism, toxic also exact inducing Reza may Direct the pathway on Dr. debate on This 2010, table. Minoxidil consensus The In the of edema. CSC. mentioned[6]. on and effect been to swelling have still the related vessels the is choroidal described defend is of association literature vasodilation and Rastmanesh, this in or vessels and epithelium data of choroidal pigmented rearrangement Scant mechanism retinal of Capillary precise diseases. proliferation CSC. retinal the for enhances many about for culprit Minoxidil events the that baseline be hypothesis the may are Minoxidil angiogenesis pathway massive on was pathophysiologic OCT was up on patient Follow Based the 3. days. Figure which 10 discontinuation, of in about Minoxidil impression in CSC after the subsided damage on with Discussion were retinal months, case improving symptoms 3 a of the almost favor After and reported in Minoxidil two. Italy, the also these stopped find in between he to colleagues relation for article, himself the culprit his that net about the and the discussed as search Scarinci and personality to Minoxidil A started Dr. increased type he was 2011 a researcher which and In a Minoxidil job as topical stressful and of the convinced dosage toward not the was was answer! but everything He CSC far, of progression. So progression this 5%. the to justify 2% to from weeks 3 these in uaeu n clrtxclg,2012. toxicology, ocular and Cutaneous None a ae rmpatient. from taken was eta hroeioah soitdwt oia s fmnxdl2 o ramn of treatment for 2% minoxidil of use topical with associated chorioretinopathy Central h uhr aen oflc fitrs odeclare. to interest of conflict no have authors The 31 2 2:p 157-159. p. (2): Posted on Authorea 18 Dec 2020 — The copyright holder is the author/funder. All rights reserved. No reuse without permission. — https://doi.org/10.22541/au.160827342.27683628/v1 — This a preprint and has not been peer reviewed. Data may be preliminary. eye-just-a-coincidence-or-is-it-fate 3.pdf Figure file Hosted eye-just-a-coincidence-or-is-it-fate 2.pdf Figure file Hosted eye-just-a-coincidence-or-is-it-fate discontinuation. 1.pdf Minoxidil after Figure dosage. days Minoxidil 10 of eye. titration right file up the Hosted After of eye. OCT right Last the 3. of Figure OCT second The 2. angiography.Figure and OCT First 1. Figure Legends Figure report. al., case et R., Venkatesh, 8. 2010. Transduction, R., Rastmanesh, 7. baldness. of treatment al., for et H., Satoh, 6. 1999. ophthalmology, al., of et H., Iijima, 5. al., 2018. et ophthalmology, D., Hanumunthadu, 4. al., et P., Treatments. Iacono, Zhang, 3. J. and Deng, meta-analysis. T. and B., Liu, 2. M ptamlg,2020. Ophthalmology, BMC urn hraetcldsg,2018. design, pharmaceutical Current vial at available at available at available eia 2016. Retina, 30 lsioe ciao niio ncnrlsru chorioretinopathy. serous central in 1 inhibitor activator Plasminogen aeo ct ycrilifrto soitdwt oia s fmnxdl(RiUP minoxidil of use topical with associated infarction myocardial acute of case A lpcaadoua leain:arl o Minoxidil? for role a alterations: ocular and Alopecia 66 3:p 189-192. p. (3): hraohrp fCnrlSru hroeioah:ARve fteCurrent the of Review A Chorioretinopathy: Serous Central of Pharmacotherapy 1) .1704. p. (12): ioii nue eta eosCoirtnptytetdwt rlEplerenone–a oral with treated Chorioretinopathy serous central induced Minoxidil 127 aaeehatjunl 2000. journal, heart Japanese https://authorea.com/users/383581/articles/499464-minoxidil-and-i- https://authorea.com/users/383581/articles/499464-minoxidil-and-i- https://authorea.com/users/383581/articles/499464-minoxidil-and-i- 4:p 477-478. p. (4): aaeeto hoi eta eoschorioretinopathy. serous central chronic of Management 36 1:p 9-19. p. (1): ikfcosfrcnrlsru hroeioah:asseai review systematic a chorioretinopathy: serous central for factors Risk 20 1:p 1-5. p. (1): 24 3 4) .4864-4873. p. (41): 41 4:p 519-523. p. (4): ora fRcposadSignal and Receptors of Journal mrcnjournal American ninjunlof journal Indian ® )